1414356-30-1

Basic information

• Product Name: (2-fluoro-4-phenoxyphenyl)-boronic acid
• Synonyms: (2-fluoro-4-phenoxyphenyl)-boronic acid
• CAS NO: 1414356-30-1
• Molecular Weight: 232.019
• Mol File: 1414356-30-1.mol

Chemical Properties

• CAS DataBase Reference: (2-fluoro-4-phenoxyphenyl)-boronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2-fluoro-4-phenoxyphenyl)-boronic acid(1414356-30-1)
• EPA Substance Registry System: (2-fluoro-4-phenoxyphenyl)-boronic acid(1414356-30-1)

Safety Data

• Hazardous Substances Data: 1414356-30-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
(2-Fluoro-4-phenoxyphenyl)-boronic acid serves as a key intermediate in organic synthesis, facilitating the creation of complex organic molecules. Its ability to form reversible covalent bonds with diols and amino alcohols makes it a useful reagent for various chemical reactions.
Used in Drug Development:
In the pharmaceutical industry, (2-fluoro-4-phenoxyphenyl)-boronic acid is employed as a building block for designing and developing new drugs. Its unique properties, including the presence of a fluorine atom, contribute to its potential as a precursor for creating molecules with enhanced biological activity and pharmaceutical efficacy.
Used in Medicinal Chemistry:
(2-Fluoro-4-phenoxyphenyl)-boronic acid is utilized in medicinal chemistry for the development of compounds with specific biological targets. (2-fluoro-4-phenoxyphenyl)-boronic acid's unique structural features and reactivity allow for the fine-tuning of drug candidates to improve their interaction with biological receptors and enzymes.
Used in Synthetic Organic Chemistry:
As a boronic acid derivative, (2-fluoro-4-phenoxyphenyl)-boronic acid is a valuable tool in synthetic organic chemistry. It is used to construct a wide array of organic compounds, including those with potential applications in materials science, agrochemicals, and other specialized fields.

Upstream product

• 98-80-6 phenylboronic acid 
• 121219-03-2 4-bromo-3-fluorophenol 
• 5419-55-6 Triisopropyl borate 
• 1138557-58-0 1-bromo-2-fluoro-4-phenoxybenzene 

Downstream Products

• 1414355-76-2 (R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carbonyl)-4-methyl-4-(piperidin-1-yl)pent-2-enenitrile 
• 1414356-04-9 N-[(1R)-2-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]-1-methylethyl]-2-cyano-4-ethoxy-4-methylpent-2-enamide 
• 1414358-13-6 N-[(1R)-2-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]-1-methyl-ethyl]-2-cyano-acetamide 
• 1414358-21-6 N-[(2S)-1-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propan-2-yl]-2-cyanoacetamide 
• 1414353-83-5 (R)-2-(2-((4-amino-3-(2-chloro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carbonyl)-3-cyclopropylacrylonitrile 
• 1414356-03-8 (S)-N-(1-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propan-2-yl)-2-cyano-4-methylpent-2-eneamide 
• 1575590-56-5 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl] azetidine-1-carbonyl]-4-methyl-pent-2-enenitrile 
• 1575590-20-3 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile 
• 1575589-42-2 2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4-(3-(tert-butyldiphenylsilyloxy)azetidin-1-yl)-4-methylpent-2-enenitrile 
• 1575589-32-0 2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4-(3-hydroxyazetidin-1-yl)-4-methylpent-2-enenitrile 
• 1575589-25-1 (R)-tert-butyl 4-(5-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-4-cyano-2-methyl-5-oxopent-3-en-2-yl)piperazine-1-carboxylate 
• 1575589-15-9 2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(piperazin-1-yl)pent-2-enenitrile 

Relevant articles and documents

BTK INHIBITORS

Compounds of the formula (I), or pharmaceutically acceptable salts thereof, which possess BTK inhibitory activity and are accordingly useful in therapy and in methods of treatment of the human or animal body. Also provided are the processes for the manufacture of said chemical compounds, the pharmaceutical compositions containing them, and their use in the manufacture of medicaments for use in a therapeutic effect in a warm-blooded animal such as man.

Purinone Derivatives as Tyrosine Kinase Inhibitors

The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as autoimmune diseases, cancer and inflammatory diseases. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.

TREATMENT OF DRY EYE

The present disclosure provides a method of treating dry eye by inhibition of Bruton's tyrosine kinase (hereinafter "BTK") inhibitors, pharmaceutical formulations comprising the same, and processes for preparing such compounds.

Tyrosine kinase inhibitors

The present disclosure provides compounds such as pyrazolpyrimidine compounds, and pharmaceutically acceptable salts thereof, that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.

PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS

The present disclosure provides compounds of Formula (LA) and/ or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of ty r-osine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and p h ar-maceutically acceptable salts thereof

REVERSIBLE COVALENT PYRROLO- OR PYRAZOLOPYRIMIDINES USEFUL FOR THE TREATMENT CANCER AND AUTOIMMUNE DISEASES

Oral pharmaceutical formulations comprising reversible covalent compounds having a Michael acceptor moiety, a process of their production, and use of these formulations for the treatment of diseases treatable by such compounds such as cancer and autoimmune diseases.

PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS

The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, Jak3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.

TYROSINE KINASE INHIBITORS

The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.